Table: q1_q4_2023_prescription_drug_wac_increases , manufacturer_name like A*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	drug_category	drug_category_source	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000077	AbbVie	03/31/2023	00074081702	(adalimumab) HUMIRA 10MG/0.1ML PFS 2-PACK	Brand	FDA	01/03/2023	512.79	6922.62	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074006702	(adalimumab) HUMIRA 1X80MG,0.8ML, 1X40MG,0.4ML PFS2PK PED CROHN'S STARTER PACK	Brand	FDA	01/03/2023	769.18	10383.96	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074061602	(adalimumab) HUMIRA 20MG/0.2ML PFS 2-PACK	Brand	FDA	01/03/2023	512.79	6922.62	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074433902	(adalimumab) HUMIRA 40MG/0.8 ML (2 PENS)	Brand	FDA	01/03/2023	512.79	6922.62	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074379902	(adalimumab) HUMIRA 40MG/0.8ML (2 SYRINGES)	Brand	FDA	01/03/2023	512.79	6922.62	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074254003	(adalimumab) HUMIRA 80MG, 0.8ML PFS 3-PACK PED CROHN'S STARTER PACK	Brand	FDA	01/03/2023	1538.37	20767.94	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074012403	(adalimumab) HUMIRA CROHN'S 80MG/0.8ML, 3 PENS STARTER PACK	Brand	FDA	01/03/2023	1538.37	20767.94	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074055402	(adalimumab) HUMIRA PEN, 40MG/0.4ML, 2 PENS	Brand	FDA	01/03/2023	512.79	6922.62	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074012402	(adalimumab) HUMIRA PEN, 80MG/0.8ML, 2 PENS	Brand	FDA	01/03/2023	1025.58	13845.27	11/11/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074024302	(adalimumab) HUMIRA PFS, 40MG/0.4ML, 2 SYRINGES	Brand	FDA	01/03/2023	512.79	6922.62	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074153903	(adalimumab) HUMIRA PSORIASIS; 1X80MG, 2X40MG (3PENS) STARTER PACK	Brand	FDA	01/03/2023	1025.58	13845.27	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074433906	(adalimumab) HUMIRA, CROHN'S, 40MG/0.8 ML (6 PENS) STARTER PACK	Brand	FDA	01/03/2023	1538.37	20767.94	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074433907	(adalimumab) HUMIRA, PSORIASIS, 40MG/0.8ML (4 PENS) STARTER PACK	Brand	FDA	01/03/2023	1025.58	13845.27	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074003828	(elagolix sodium) ORILISSA 150MG TABS, 4X7 PACK	Brand	FDA	01/03/2023	52.33	1098.99	09/01/2036	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074003956	(elagolix sodium) ORILISSA 200MG TABS, 4X14 PACK	Brand	FDA	01/03/2023	52.33	1098.99	03/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	06/30/2023	00074101756	(ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; ELAGOLIX SODIUM) ORIAHNN CAPSULES 300MG/1MG/0.5MG; 4x14	Brand	FDA	04/03/2023	52.33	1098.99	07/23/2039	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074244003	(leuprolide acetate) LUPRON DEPOT PED, 15 MG PDS KIT	Brand	FDA	01/03/2023	187.13	3929.75	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074377903	(leuprolide acetate) LUPRON DEPOT PED, 3MONTH, 11.25MG	Brand	FDA	01/03/2023	509.71	10703.92	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074969403	(leuprolide acetate) LUPRON DEPOT PED, 3MONTH, 30MG	Brand	FDA	01/03/2023	561.40	11789.30	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074210803	(leuprolide acetate) LUPRON DEPOT PED, 7.5 MG PDS KIT	Brand	FDA	01/03/2023	93.59	1965.30	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074366303	(leuprolide acetate) LUPRON DEPOT, GYN,3 MONTH 11.25 MG PDS KIT	Brand	FDA	01/03/2023	233.38	4901.02	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074364103	(leuprolide acetate) LUPRON DEPOT, GYN,3.75 MG PDS KIT	Brand	FDA	01/03/2023	77.79	1633.66	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074334603	(leuprolide acetate) LUPRON DEPOT, URO,3 MONTH 22.5 MG PDS KIT	Brand	FDA	01/03/2023	278.11	5840.26	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074368303	(leuprolide acetate) LUPRON DEPOT, URO,4 MONTH 30 MG PDS KIT	Brand	FDA	01/03/2023	370.81	7787.03	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074364203	(leuprolide acetate) LUPRON DEPOT, URO,7.5 MG PDS KIT	Brand	FDA	01/03/2023	92.70	1946.76	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074228203	(leuprolide acetate) LUPRON DEPOT-PED 11.25 MG PDS KIT	Brand	FDA	01/03/2023	169.90	3567.96	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074347303	(leuprolide acetate) LUPRON, URO,45MG 6MTH	Brand	FDA	01/03/2023	556.22	11680.71	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00032121201	(lipase/protease/amylase) CREON 12000USP DELAYED-RELEASE 100CAP	Brand	FDA	01/03/2023	18.84	395.56	06/08/2037	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00032121207	(lipase/protease/amylase) CREON 12000USP DELAYED-RELEASE 250CAP	Brand	FDA	01/03/2023	47.09	988.88	06/08/2037	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00032122401	(lipase/protease/amylase) CREON 24000USP DELAYED-RELEASE 100CAP	Brand	FDA	01/03/2023	37.34	784.07	06/08/2037	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00032122407	(lipase/protease/amylase) CREON 24000USP DELAYED-RELEASE 250CAP	Brand	FDA	01/03/2023	91.84	1928.59	06/08/2037	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00032120370	(lipase/protease/amylase) CREON 3000USP DELAYED-RELEASE 70CAP	Brand	FDA	01/03/2023	5.57	117.00	06/08/2037	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00032301613	(lipase/protease/amylase) CREON 36000USP DELAYED-RELEASE 100CAP	Brand	FDA	01/03/2023	56.69	1190.51	06/08/2037	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00032301628	(lipase/protease/amylase) CREON 36000USP DELAYED-RELEASE 250CAP	Brand	FDA	01/03/2023	141.71	2975.91	06/08/2037	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00032120601	(lipase/protease/amylase) CREON 6000USP DELAYED-RELEASE 100CAP	Brand	FDA	01/03/2023	9.42	197.89	06/08/2037	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00032120607	(lipase/protease/amylase) CREON 6000USP DELAYED-RELEASE 250CAP	Brand	FDA	01/03/2023	23.56	494.78	06/08/2037	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074204202	(risankizumab-rzaa) SKYRIZI 75MG/0.83ML PFS x2 US/PR	Brand	Medispan	01/03/2023	1461.82	19734.61	09/06/2033	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074230630	(upadacitinib) RINVOQ 15MG 30 DAY BOTTLE	Brand	FDA	01/03/2023	453.70	6124.96	10/17/2036	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074057634	(venetoclax) VENCLEXTA 100MG BOTTLE 180 TABLETS*	Brand	FDA	01/03/2023	1451.76	22191.12	09/06/2033	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074057622	(venetoclax) VENCLEXTA 100MG BOTTLE, 120 TABLETS*	Brand	FDA	01/03/2023	967.84	14794.08	09/06/2033	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074057611	(venetoclax) VENCLEXTA 100MG UNIT DOSE, 1 TABLET*	Brand	FDA	01/03/2023	8.06	123.27	09/06/2033	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074056111	(venetoclax) VENCLEXTA 10MG UNIT DOSE, 2 TABLETS*	Brand	FDA	01/03/2023	1.61	24.65	09/06/2033	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074056114	(venetoclax) VENCLEXTA 10MG WALLET, 2 TABLETS X 7*	Brand	FDA	01/03/2023	11.29	172.59	09/06/2033	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074056611	(venetoclax) VENCLEXTA 50MG UNIT DOSE, 1 TABLET*	Brand	FDA	01/03/2023	4.03	61.64	09/06/2033	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074056607	(venetoclax) VENCLEXTA 50MG WALLET, 1 TABLET X 7*	Brand	FDA	01/03/2023	28.23	431.50	09/06/2033	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074057928	(venetoclax) VENCLEXTA START PACK, 4X7 DAY WALLET*	Brand	FDA	01/03/2023	208.89	3193.05	09/06/2033	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000018	ACADIA Pharmaceuticals Inc.	12/31/2023	63090034030	Nuplazid Oral Capsule 34mg, 30 Each, Bottle	Brand	FDA	10/01/2023	430.00	4995.00	04/29/2030	Single Source Drug	None	1	ACADIA prices our medicines to reflect their value to patients, payers and society. Our goals are to reduce the burden of disease and deliver better health outcomes with our therapies.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	Prior to 2020, Acadia did not have any patent dates that extended beyond 2030. Companies typically rely on the furthest out expiration date when determining LOE, hence the 2030 date that was provided on our submission. The patents with expiration dates past 2030 in the FDA’s database are of a different type (formulation and method of use compared to composition of the matter). It’s unreasonable to assume they will remain in effect for their full terms. Once we have any clarity on the expiration date of those patents, we may adjust our LOE thinking.
Rx0000018	ACADIA Pharmaceuticals Inc.	12/31/2023	63090010030	Nuplazid Oral Tablet 10mg, 30 Each, Bottle	Brand	FDA	10/01/2023	430.00	4995.00	04/29/2030	Single Source Drug	None	1	ACADIA prices our medicines to reflect their value to patients, payers and society. Our goals are to reduce the burden of disease and deliver better health outcomes with our therapies.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	Prior to 2020, Acadia did not have any patent dates that extended beyond 2030. Companies typically rely on the furthest out expiration date when determining LOE, hence the 2030 date that was provided on our submission. The patents with expiration dates past 2030 in the FDA’s database are of a different type (formulation and method of use compared to composition of the matter). It’s unreasonable to assume they will remain in effect for their full terms. Once we have any clarity on the expiration date of those patents, we may adjust our LOE thinking.
Rx0000278	Acella Pharamceuticals, LLC	03/31/2023	42192060845	Gabapentin Oral Solution 250 MG/5ML Pkg size 5	Generic	FDA	02/01/2023	12.36	149.74	None	Non-innovator Multiple Source Drug	2432	None	increase in manufacturing costs	None	none	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000278	Acella Pharamceuticals, LLC	03/31/2023	42192060840	Gabapentin Oral Solution 300 MG/6ML Pkg size 6	Generic	FDA	02/01/2023	12.36	149.74	None	Non-innovator Multiple Source Drug	42418	None	increase in manufacturing costs	None	none	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000513	Acertis Pharmaceuticals LLC	09/30/2023	72989037230	Prometrium (progesterone, USP) Capsules 100mg 30ct	Brand	FDA	08/01/2023	100.25	500.25	None	Single Source Drug	None	1	Factors Leading to WAC Price Increase (Including but not limited to): - Current Economic Conditions: The current economic environment has posed challenges, including increased production and operational costs, necessitating a WAC price adjustment. - Current Inflationary Environment: Escalating inflation rates have impacted various aspects of our operations, leading to increased expenses and, consequently, a WAC price increase. - Increased Costs in Sales and Marketing: Our commitment to maintaining high-quality sales and marketing efforts has required increased investments, contributing to the need for a WAC price adjustment. - Rising Distribution Costs: The costs associated with product distribution have risen significantly, driven by various market factors, prompting the WAC price increase.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000513	Acertis Pharmaceuticals LLC	09/30/2023	72989037330	Prometrium (progesterone, USP) Capsules 200mg 30ct	Brand	FDA	08/01/2023	190.06	950.28	None	Single Source Drug	None	1	Factors Leading to WAC Price Increase (Including but not limited to): - Current Economic Conditions: The current economic environment has posed challenges, including increased production and operational costs, necessitating a WAC price adjustment. - Current Inflationary Environment: Escalating inflation rates have impacted various aspects of our operations, leading to increased expenses and, consequently, a WAC price increase. - Increased Costs in Sales and Marketing: Our commitment to maintaining high-quality sales and marketing efforts has required increased investments, contributing to the need for a WAC price adjustment. - Rising Distribution Costs: The costs associated with product distribution have risen significantly, driven by various market factors, prompting the WAC price increase.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000021	Acorda Therapeutics, Inc.	03/31/2023	10144042760	Ampyra Oral Tablet Extended Release 12 Hour 10 MG Package Size 60 Package Quantity 1	Brand	FDA	01/01/2023	351.81	3869.92	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000021	Acorda Therapeutics, Inc.	03/31/2023	10144034260	Inbrija Inhalation Capsule 42 MG Package Size 60 Package Quantity 1	Brand	FDA	01/01/2023	104.74	1152.12	11/16/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000157	Acrotech Biopharma LLC	09/30/2023	72893000201	Beleodaq Intravenous Solution Reconstituted 500 MG, 1 Each, Unit-Dose, Vial	Brand	FDA	07/01/2023	34.83	2357.05	10/27/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	NDC change from 68152-0108-09 to 72893-0002-01 on 1/1/2020.
Rx0000251	Actelion Pharmaceuticals US, Inc	03/31/2023	66215050115	OPSUMIT® (macitentan)Strength:10 mg Package Size:15 Form:Tablet	Brand	FDA	01/20/2023	447.39	6039.82	04/18/2029	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2023.
Rx0000251	Actelion Pharmaceuticals US, Inc	03/31/2023	66215050130	OPSUMIT® (macitentan)Strength:10 mg Package Size:30 Form:Tablet	Brand	FDA	01/20/2023	894.79	12079.65	04/18/2029	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2023.
Rx0000251	Actelion Pharmaceuticals US, Inc	03/31/2023	66215061006	UPTRAVI® (selexipag) Strength:1000 mcg Package Size:60 Form:Tablet	Brand	FDA	01/20/2023	1036.23	22183.77	12/01/2036	Innovator Multiple Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2023.
Rx0000251	Actelion Pharmaceuticals US, Inc	03/31/2023	66215061206	UPTRAVI® (selexipag) Strength:1200 mcg Package Size:60 Form:Tablet	Brand	FDA	01/20/2023	1036.23	22183.77	12/01/2036	Innovator Multiple Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2023.
Rx0000251	Actelion Pharmaceuticals US, Inc	03/31/2023	66215061406	UPTRAVI® (selexipag) Strength:1400 mcg Package Size:60 Form:Tablet	Brand	FDA	01/20/2023	1036.23	22183.77	12/01/2036	Innovator Multiple Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2023.
Rx0000251	Actelion Pharmaceuticals US, Inc	03/31/2023	66215061606	UPTRAVI® (selexipag) Strength:1600 mcg Package Size:60 Form:Tablet	Brand	FDA	01/20/2023	1036.23	22183.77	12/01/2036	Innovator Multiple Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2023.
Rx0000251	Actelion Pharmaceuticals US, Inc	03/31/2023	66215060214	UPTRAVI® (selexipag) Strength:200 mcg Package Size:140 Form:Tablet	Brand	FDA	01/20/2023	1554.74	33284.04	12/01/2036	Innovator Multiple Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2023.
Rx0000251	Actelion Pharmaceuticals US, Inc	03/31/2023	66215060206	UPTRAVI® (selexipag) Strength:200 mcg Package Size:60 Form:Tablet	Brand	FDA	01/20/2023	666.32	14264.59	12/01/2036	Innovator Multiple Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2023.
Rx0000251	Actelion Pharmaceuticals US, Inc	03/31/2023	66215062820	UPTRAVI® (selexipag) Strength:200+800 mcg Package Size:200 Form:Tablet	Brand	FDA	01/20/2023	1554.72	33283.77	12/01/2036	Innovator Multiple Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2023.
Rx0000251	Actelion Pharmaceuticals US, Inc	03/31/2023	66215060406	UPTRAVI® (selexipag) Strength:400 mcg Package Size:60 Form:Tablet	Brand	FDA	01/20/2023	1036.23	22183.77	12/01/2036	Innovator Multiple Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2023.
Rx0000251	Actelion Pharmaceuticals US, Inc	03/31/2023	66215060606	UPTRAVI® (selexipag) Strength:600 mcg Package Size:60 Form:Tablet	Brand	FDA	01/20/2023	1036.23	22183.77	12/01/2036	Innovator Multiple Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2023.
Rx0000251	Actelion Pharmaceuticals US, Inc	03/31/2023	66215060806	UPTRAVI® (selexipag) Strength:800 mcg Package Size:60 Form:Tablet	Brand	FDA	01/20/2023	1036.23	22183.77	12/01/2036	Innovator Multiple Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2023.
Rx0000328	Adamas Pharmaceuticals, Inc.	03/31/2023	70482017060	Gocovri Oral Capsule Extended Release 24 Hour 137 MG Package Size 60 Package Quantity 1	Brand	FDA	01/01/2023	149.67	3142.96	08/23/2038	Single Source Drug	None	1	None	1	No change or improvement to the drug.	None	11/24/2021	Adamas Pharmaceuticals	None	1	Information regarding the purchase of Adamas Pharmaceuticals can be found in press releases, however, information regarding specific product pricing is not available.	2715.00	2636.00	2017	2375.00	None	None
Rx0000328	Adamas Pharmaceuticals, Inc.	03/31/2023	70482008560	Gocovri Oral Capsule Extended Release 24 Hour 68.5 MG Package Size 60 Package Quantity 1	Brand	FDA	01/01/2023	149.67	3142.96	08/23/2038	Single Source Drug	None	1	None	1	No change or improvement to the drug.	None	11/24/2021	Adamas Pharmaceuticals	None	1	Information regarding the purchase of Adamas Pharmaceuticals can be found in press releases, however, information regarding specific product pricing is not available.	2715.00	2636.00	2017	2375.00	None	None
Rx0000328	Adamas Pharmaceuticals, Inc.	03/31/2023	70482007530	Osmolex ER Oral Tablet Extended Release 24 Hour 129 MG Package Size 30 Package Quantity 1	Brand	FDA	01/01/2023	48.96	543.51	02/15/2038	Single Source Drug	None	1	None	1	No change or improvement to the drug.	None	11/24/2021	Adamas Pharmaceuticals	None	1	Information regarding the purchase of Adamas Pharmaceuticals can be found in press releases, however, information regarding specific product pricing is not available.	450.00	450.00	2018	450.00	None	None
Rx0000328	Adamas Pharmaceuticals, Inc.	03/31/2023	70482007630	Osmolex ER Oral Tablet Extended Release 24 Hour 193 MG Package Size 30 Package Quantity 1	Brand	FDA	01/01/2023	48.96	543.51	02/15/2038	Single Source Drug	None	1	None	1	No change or improvement to the drug.	None	11/24/2021	Adamas Pharmaceuticals	None	1	Information regarding the purchase of Adamas Pharmaceuticals can be found in press releases, however, information regarding specific product pricing is not available.	450.00	450.00	2018	450.00	None	None
Rx0000477	Agile Therapeutics	09/30/2023	71671010003	Twirla Transdermal Patch Weekly 120-30 MCG/24HR, 1 Each, Unit-of-Use, Box Qty 3	Brand	FDA	07/17/2023	13.37	204.57	08/26/2028	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000477	Agile Therapeutics	09/30/2023	71671010011	Twirla Transdermal Patch Weekly 120-30 MCG/24HR, 1 Each, Unit-of-Use, Package	Brand	FDA	07/17/2023	4.46	68.19	08/26/2028	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000222	Aimmune Therapeutics	03/31/2023	71881010415	PALFORZIA - 1-20mg Capsules per package	Brand	FDA	01/07/2023	139.26	584.26	03/12/2034	Single Source Drug	None	1	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	None	None	None	None	None	None	None	None	None	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=735	None
Rx0000222	Aimmune Therapeutics	03/31/2023	71881010730	PALFORZIA - 1-20mg/1-100mg Capsules per package	Brand	FDA	01/07/2023	139.26	584.26	03/12/2034	Single Source Drug	None	1	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	None	None	None	None	None	None	None	None	None	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=738	None
Rx0000222	Aimmune Therapeutics	03/31/2023	71881011115	PALFORZIA - 15 Sachet-300mg per package	Brand	FDA	01/07/2023	139.26	584.26	03/12/2034	Single Source Drug	None	1	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	None	None	None	None	None	None	None	None	None	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=742	None
Rx0000222	Aimmune Therapeutics	03/31/2023	71881010930	PALFORZIA - 2-100mg Capsules per package	Brand	FDA	01/07/2023	139.26	584.26	03/12/2034	Single Source Drug	None	1	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	None	None	None	None	None	None	None	None	None	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=740	None
Rx0000222	Aimmune Therapeutics	03/31/2023	71881010345	PALFORZIA - 2-1mg/1-10mg Capsules per package	Brand	FDA	01/07/2023	139.26	584.26	03/12/2034	Single Source Drug	None	1	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	None	None	None	None	None	None	None	None	None	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=734	None
Rx0000222	Aimmune Therapeutics	03/31/2023	71881010530	PALFORZIA - 2-20mg Capsules per package	Brand	FDA	01/07/2023	139.26	584.26	03/12/2034	Single Source Drug	None	1	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	None	None	None	None	None	None	None	None	None	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=736	None
Rx0000222	Aimmune Therapeutics	03/31/2023	71881011060	PALFORZIA - 2-20mg/2-100mg Capsules per package	Brand	FDA	01/07/2023	139.26	584.26	03/12/2034	Single Source Drug	None	1	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	None	None	None	None	None	None	None	None	None	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=741	None
Rx0000222	Aimmune Therapeutics	03/31/2023	71881011130	PALFORZIA - 30 Sachet-300mg per package	Brand	FDA	01/07/2023	278.52	168.52	03/12/2034	Single Source Drug	None	1	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	None	None	None	None	None	None	None	None	None	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=743	None
Rx0000222	Aimmune Therapeutics	03/31/2023	71881010145	PALFORZIA - 3-1mg Capsules per package	Brand	FDA	01/07/2023	139.26	584.26	03/12/2034	Single Source Drug	None	1	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	None	None	None	None	None	None	None	None	None	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=732	None
Rx0000222	Aimmune Therapeutics	03/31/2023	71881010860	PALFORZIA - 3-20mg/1-100mg Capsules per package	Brand	FDA	01/07/2023	139.26	584.26	03/12/2034	Single Source Drug	None	1	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	None	None	None	None	None	None	None	None	None	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=739	None
Rx0000222	Aimmune Therapeutics	03/31/2023	71881010660	PALFORZIA - 4-20mg Capsules per package	Brand	FDA	01/07/2023	139.26	584.26	03/12/2034	Single Source Drug	None	1	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	None	None	None	None	None	None	None	None	None	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=737	None
Rx0000222	Aimmune Therapeutics	03/31/2023	71881010290	PALFORZIA - 6-1mg Capsules per package	Brand	FDA	01/07/2023	139.26	584.26	03/12/2034	Single Source Drug	None	1	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	None	None	None	None	None	None	None	None	None	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=733	None
Rx0000222	Aimmune Therapeutics	12/31/2023	73562010410	VIOKACE - 100 Tablet - 10,440 unit - 39,150 unit - 39,150 unit per package	Brand	FDA	12/31/2023	100.71	422.51	None	Single Source Drug	None	1	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	05/11/2020	Allergan	None	1	None	293.88	293.88	2012	221.00	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=714	None
Rx0000222	Aimmune Therapeutics	12/31/2023	73562020810	VIOKACE - 100 Tablet - 20,800 unit - 78,300 unit - 78,300 unit per package	Brand	FDA	12/31/2023	198.67	833.54	None	Single Source Drug	None	1	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	05/11/2020	Allergan	None	1	None	579.79	579.79	2012	436.00	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=715	None
Rx0000400	AkaRx, Inc., a Sobi Company	03/31/2023	71369002010	DOPTELET, 1 BLISTER PACK in 1 CARTON > 10 TABLET, EQ 20MG BASE	Brand	FDA	01/01/2023	186.70	3920.10	05/05/2025	Single Source Drug	None	1	AkaRx Inc. pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including but not limited to the clinical value of the medicine, the economic value of the medicine, and market dynamics and competitor pricing.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000400	AkaRx, Inc., a Sobi Company	03/31/2023	71369002015	DOPTELET, 1 BLISTER PACK in 1 CARTON > 15 TABLET, EQ 20MG BASE	Brand	FDA	01/01/2023	280.05	5880.15	05/05/2025	Single Source Drug	None	1	AkaRx Inc. pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including but not limited to the clinical value of the medicine, the economic value of the medicine, and market dynamics and competitor pricing.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000400	AkaRx, Inc., a Sobi Company	03/31/2023	71369002030	DOPTELET, 2 BLISTER PACK in 1 CARTON / 15 TABLET, FILM COATED in 1 BLISTER PACK, EQ 20MG BASE	Brand	FDA	01/01/2023	560.10	11760.30	05/05/2025	Single Source Drug	None	1	AkaRx Inc. pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including but not limited to the clinical value of the medicine, the economic value of the medicine, and market dynamics and competitor pricing.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000417	Akebia Therapeutics, Inc.	03/31/2023	59922063101	Auryxia (Ferric Citrate) 210 mg, 200 Tablets per Bottle	Brand	FDA	01/01/2023	64.00	1458.00	07/21/2030	Single Source Drug	None	1	Akebia Therapeutics’ pricing decisions factor in multiple variables and considerations including but not limited to: competitive and market dynamics, increasing supply chain and overhead costs, distribution and wholesaler fees, and research and development costs.	None	None	1	None	None	None	None	None	None	None	None	None	None	Auryxia was developed by Keryx Biopharmaceuticals. In December 2018, Keryx Biopharmaceuticals and Akebia Therapeutics merged. Keryx Biopharmaceuticals is now a wholly owned subsidiary of Akebia Therapeutics. Auryxia is not an acquired product based on this history.
Rx0000417	Akebia Therapeutics, Inc.	09/30/2023	59922063101	Auryxia (Ferric Citrate) 210 mg, 200 Tablets per Bottle	Brand	FDA	07/01/2023	32.00	1490.00	07/21/2030	Single Source Drug	None	1	Akebia Therapeutics’ pricing decisions factor in multiple variables and considerations including but not limited to: competitive and market dynamics, increasing supply chain and overhead costs, distribution and wholesaler fees, and research and development costs.	None	None	1	None	None	None	None	None	None	None	None	None	None	Auryxia was developed by Keryx Biopharmaceuticals. In December 2018, Keryx Biopharmaceuticals and Akebia Therapeutics merged. Keryx Biopharmaceuticals is now a wholly owned subsidiary of Akebia Therapeutics. Auryxia is not an acquired product based on this history.
Rx0000235	Alembic Pharmaceuticals, Inc.	03/31/2023	62332001491	Lithium Carbonate Capsules USP 300mg 1000ct	Generic	FDA	01/30/2023	1314.40	1369.90	None	Non-innovator Multiple Source Drug	1	None	75% - Our current Active Ingredient supplier will no longer supply this product to Alembic. We have contacted an alternate supplier and the cost for Lithium Carbonate active ingredient has increased significantly. In addition, we must run additional tests and submit information to FDA prior to selling our Lithium Carbonate capsules with a different active ingredient supplier than what is currently in our ANDA filing. 25% - Market conditions and lack of supply has made it possible to increase price to offset added costs and provide additional profit for this product moving forward.	None	There has been no change or improvement to Lithium Carbonate, just a change of supplier for the active ingredient.	None	None	None	None	None	None	None	None	None	None	None	There were no sales for this product in the previous year. The system would not allow 0 as a submission, so 1 was used instead.
Rx0000235	Alembic Pharmaceuticals, Inc.	03/31/2023	62332001431	Lithium Carbonate Capsules USP 300mg 100ct	Generic	FDA	01/30/2023	130.53	136.99	None	Non-innovator Multiple Source Drug	1	None	75% - Our current Active Ingredient supplier will no longer supply this product to Alembic. We have contacted an alternate supplier and the cost for Lithium Carbonate active ingredient has increased significantly. In addition, we must run additional tests and submit information to FDA prior to selling our Lithium Carbonate capsules with a different active ingredient supplier than what is currently in our ANDA filing. 25% - Market conditions and lack of supply has made it possible to increase price to offset added costs and provide additional profit for this product moving forward.	None	There has been no change or improvement to Lithium Carbonate, just a change of supplier for the active ingredient.	None	None	None	None	None	None	None	None	None	None	None	There were no sales for this product in the previous year. The system would not allow 0 as a submission, so 1 was used instead.
Rx0000235	Alembic Pharmaceuticals, Inc.	03/31/2023	62332001531	Lithium Carbonate Capsules USP 600mg 100ct	Generic	FDA	01/30/2023	128.52	150.00	None	Non-innovator Multiple Source Drug	1	None	75% - Our current Active Ingredient supplier will no longer supply this product to Alembic. We have contacted an alternate supplier and the cost for Lithium Carbonate active ingredient has increased significantly. In addition, we must run additional tests and submit information to FDA prior to selling our Lithium Carbonate capsules with a different active ingredient supplier than what is currently in our ANDA filing. 25% - Market conditions and lack of supply has made it possible to increase price to offset added costs and provide additional profit for this product moving forward.	None	There has been no change or improvement to Lithium Carbonate, just a change of supplier for the active ingredient.	None	None	None	None	None	None	None	None	None	None	None	There were no sales for this product in the previous year. The system would not allow 0 as a submission, so 1 was used instead.
Rx0000272	Alexion Pharmaceuticals	12/31/2023	00310061028	CAPSULE 10MG 28 Count Bottle	Brand	FDA	10/01/2023	73.59	2526.45	12/12/2026	Innovator Multiple Source Drug	2296	None	When setting the price of medicines Alexion, AstraZeneca Rare Disease aims to reflect its value to patients, to payers, and to society in general as well as the cost of research and development (R&D). Alexion’s pricing decisions are based on many factors that reflect our commitment to patients, global macroeconomic realities, and the US Healthcare System as well as our obligation to shareholders. We are mindful of healthcare costs and are working to explore innovative opportunities and solutions working with others in the US Healthcare system to deliver innovative medicines while considering cost and value. Importantly, the WAC or list price is rarely the price paid by an individual patient as it does not account for a series of factors, including individual insurance plan design, provider access, assistance programs or savings offers.	None	No changes to report, product launched on 05/20/2021	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000272	Alexion Pharmaceuticals	12/31/2023	00310061060	CAPSULE 10MG 60 Count Bottle	Brand	FDA	10/01/2023	157.68	5413.69	12/12/2026	Innovator Multiple Source Drug	18068	None	When setting the price of medicines Alexion, AstraZeneca Rare Disease aims to reflect its value to patients, to payers, and to society in general as well as the cost of research and development (R&D). Alexion’s pricing decisions are based on many factors that reflect our commitment to patients, global macroeconomic realities, and the US Healthcare System as well as our obligation to shareholders. We are mindful of healthcare costs and are working to explore innovative opportunities and solutions working with others in the US Healthcare system to deliver innovative medicines while considering cost and value. Importantly, the WAC or list price is rarely the price paid by an individual patient as it does not account for a series of factors, including individual insurance plan design, provider access, assistance programs or savings offers.	None	No changes to report, product launched on 05/20/2021	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000272	Alexion Pharmaceuticals	12/31/2023	00310062528	CAPSULE 25MG 28 Count Bottle	Brand	FDA	10/01/2023	183.96	6315.97	12/12/2026	Innovator Multiple Source Drug	1264	None	When setting the price of medicines Alexion, AstraZeneca Rare Disease aims to reflect its value to patients, to payers, and to society in general as well as the cost of research and development (R&D). Alexion’s pricing decisions are based on many factors that reflect our commitment to patients, global macroeconomic realities, and the US Healthcare System as well as our obligation to shareholders. We are mindful of healthcare costs and are working to explore innovative opportunities and solutions working with others in the US Healthcare system to deliver innovative medicines while considering cost and value. Importantly, the WAC or list price is rarely the price paid by an individual patient as it does not account for a series of factors, including individual insurance plan design, provider access, assistance programs or savings offers.	None	No changes to report, product launched on 05/20/2021	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000272	Alexion Pharmaceuticals	12/31/2023	00310062560	CAPSULE 25MG 60 Count Bottle	Brand	FDA	10/01/2023	394.20	13534.23	12/12/2026	Innovator Multiple Source Drug	8290	None	When setting the price of medicines Alexion, AstraZeneca Rare Disease aims to reflect its value to patients, to payers, and to society in general as well as the cost of research and development (R&D). Alexion’s pricing decisions are based on many factors that reflect our commitment to patients, global macroeconomic realities, and the US Healthcare System as well as our obligation to shareholders. We are mindful of healthcare costs and are working to explore innovative opportunities and solutions working with others in the US Healthcare system to deliver innovative medicines while considering cost and value. Importantly, the WAC or list price is rarely the price paid by an individual patient as it does not account for a series of factors, including individual insurance plan design, provider access, assistance programs or savings offers.	None	No changes to report, product launched on 05/20/2021	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000272	Alexion Pharmaceuticals	06/30/2023	00310061028	KOSELUGO Caps 10mg (28ct)	Brand	FDA	04/01/2023	94.34	2452.86	12/12/2026	Innovator Multiple Source Drug	1451	None	When setting the price of medicines Alexion, AstraZeneca Rare Disease aims to reflect its value to patients, to payers, and to society in general as well as the cost of research and development (R&D). Alexion’s pricing decisions are based on many factors that reflect our commitment to patients, global macroeconomic realities, and the US Healthcare System as well as our obligation to shareholders. We are mindful of healthcare costs and are working to explore innovative opportunities and solutions working with others in the US Healthcare system to deliver innovative medicines while considering cost and value. Importantly, the WAC or list price is rarely the price paid by an individual patient as it does not account for a series of factors, including individual insurance plan design, provider access, assistance programs or savings offers.	None	No changes to report, product launched on 05/20/2021.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000272	Alexion Pharmaceuticals	06/30/2023	00310061060	KOSELUGO Caps 10mg (60ct)	Brand	FDA	04/01/2023	202.15	5256.01	12/12/2026	Innovator Multiple Source Drug	17650	None	When setting the price of medicines Alexion, AstraZeneca Rare Disease aims to reflect its value to patients, to payers, and to society in general as well as the cost of research and development (R&D). Alexion’s pricing decisions are based on many factors that reflect our commitment to patients, global macroeconomic realities, and the US Healthcare System as well as our obligation to shareholders. We are mindful of healthcare costs and are working to explore innovative opportunities and solutions working with others in the US Healthcare system to deliver innovative medicines while considering cost and value. Importantly, the WAC or list price is rarely the price paid by an individual patient as it does not account for a series of factors, including individual insurance plan design, provider access, assistance programs or savings offers.	None	No changes to report, product launched on 04/10/2020.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000272	Alexion Pharmaceuticals	06/30/2023	00310062528	KOSELUGO Caps 25mg (28ct)	Brand	FDA	04/01/2023	235.85	6132.01	12/12/2026	Innovator Multiple Source Drug	820	None	When setting the price of medicines Alexion, AstraZeneca Rare Disease aims to reflect its value to patients, to payers, and to society in general as well as the cost of research and development (R&D). Alexion’s pricing decisions are based on many factors that reflect our commitment to patients, global macroeconomic realities, and the US Healthcare System as well as our obligation to shareholders. We are mindful of healthcare costs and are working to explore innovative opportunities and solutions working with others in the US Healthcare system to deliver innovative medicines while considering cost and value. Importantly, the WAC or list price is rarely the price paid by an individual patient as it does not account for a series of factors, including individual insurance plan design, provider access, assistance programs or savings offers.	None	No changes to report, product launched on 05/20/2021.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000272	Alexion Pharmaceuticals	06/30/2023	00310062560	KOSELUGO Caps 25mg (60ct)	Brand	FDA	04/01/2023	505.39	13140.03	12/12/2026	Innovator Multiple Source Drug	7869	None	When setting the price of medicines Alexion, AstraZeneca Rare Disease aims to reflect its value to patients, to payers, and to society in general as well as the cost of research and development (R&D). Alexion’s pricing decisions are based on many factors that reflect our commitment to patients, global macroeconomic realities, and the US Healthcare System as well as our obligation to shareholders. We are mindful of healthcare costs and are working to explore innovative opportunities and solutions working with others in the US Healthcare system to deliver innovative medicines while considering cost and value. Importantly, the WAC or list price is rarely the price paid by an individual patient as it does not account for a series of factors, including individual insurance plan design, provider access, assistance programs or savings offers.	None	No changes to report, product launched on 04/10/2020.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000208	Almatica	09/30/2023	52427065830	Loreev XR Capsule, 1mg 30 Count	Brand	FDA	08/07/2023	21.25	446.25	01/08/2034	Single Source Drug	3557	None	Almatica considers various factors in deciding the wholesale acquisition cost (WAC) at which to set its prescription drugs, including Loreev.  These factors include, but are not limited to: market based factors such as the competitive landscape and pricing environment; manufacturing and supply considerations; profitability; inflation and costs, including increased cost of administrative and commercial activities; therapeutic class and patient population, as well as patient needs and access; and contracts and relationships with customers.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000208	Almatica	09/30/2023	52427066330	Loreev XR Capsules 2mg 30 Count	Brand	FDA	08/07/2023	21.25	446.25	01/08/2034	Single Source Drug	2301	None	Almatica considers various factors in deciding the wholesale acquisition cost (WAC) at which to set its prescription drugs, including Loreev.  These factors include, but are not limited to: market based factors such as the competitive landscape and pricing environment; manufacturing and supply considerations; profitability; inflation and costs, including increased cost of administrative and commercial activities; therapeutic class and patient population, as well as patient needs and access; and contracts and relationships with customers.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000208	Almatica	09/30/2023	52427066730	Loreev XR Capsules, 3mg 30 Count	Brand	FDA	08/07/2023	21.25	446.25	01/08/2034	Single Source Drug	1943	None	Almatica considers various factors in deciding the wholesale acquisition cost (WAC) at which to set its prescription drugs, including Loreev.  These factors include, but are not limited to: market based factors such as the competitive landscape and pricing environment; manufacturing and supply considerations; profitability; inflation and costs, including increased cost of administrative and commercial activities; therapeutic class and patient population, as well as patient needs and access; and contracts and relationships with customers.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000459	AltaThera Pharmaceuticals LLC	03/31/2023	69724011210	Sotalol hydrochloride 15mg/mL 10mL Vial	Brand	FDA	01/01/2023	265.00	2999.00	08/21/2039	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2023	59212042510	DONNATAL 16.2MG 100 Bottle	Brand	Medispan	04/01/2023	60.00	1263.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2023	59212042304	DONNATAL 16.2MG/5ML 118ML GRP Bottle	Brand	Medispan	04/01/2023	23.00	473.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2023	59212042204	DONNATAL 16.2MG/5ML 118ML MINT, Bottle	Brand	Medispan	04/01/2023	23.00	473.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2023	59212042316	DONNATAL 16.2MG/5ML 473ML GRP Bottle	Brand	Medispan	04/01/2023	94.00	1889.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2023	59212042216	DONNATAL 16.2MG/5ML 473ML MINT Bottle	Brand	Medispan	04/01/2023	94.00	1889.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2023	59212000301	DYRENIUM 100MG 100 Capsule	Brand	FDA	04/01/2023	60.00	1340.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2023	59212000201	DYRENIUM 50MG 100 Capsule	Brand	FDA	04/01/2023	77.00	1340.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2023	59212065860	KAPVAY 0.1MG 60 ER 60 Each, Bottle	Brand	Medispan	04/01/2023	30.00	530.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2023	59212024055	LANOXIN 0.0625MG 100 Bottle	Brand	FDA	04/01/2023	90.00	1655.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2023	59212024255	LANOXIN 0.125MG 100 Bottle	Brand	FDA	04/01/2023	90.00	1655.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2023	59212024256	LANOXIN 0.125MG 10X10UD Box	Brand	FDA	04/01/2023	90.00	1655.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2023	59212024955	LANOXIN 0.25MG 100 Bottle	Brand	FDA	04/01/2023	90.00	1655.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2023	59212044710	PARNATE 10MG 100 Tablet	Brand	FDA	04/01/2023	39.00	889.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	09/30/2023	59212056210	Plaquenil Oral Tablet 200 MG, 100 Each, Bottle	Brand	FDA	07/01/2023	58.00	1268.00	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2023	59212020010	UROXATRAL 10MG 100 ER Bottle	Brand	FDA	04/01/2023	115.00	2675.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2023	59212068010	ZONEGRAN 100MG 100 Each, Bottle	Brand	FDA	04/01/2023	101.00	2121.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2023	59212068110	ZONEGRAN 25MG 100 Each, Bottle	Brand	FDA	04/01/2023	78.00	1638.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000231	American Health Packaging	03/31/2023	68084038801	BENZTROPINE MESYLATE 1mg Tab 100UD	Generic	FDA	02/24/2023	7.19	49.00	None	Non-innovator Multiple Source Drug	4992	None	Market Conditions	None	No Change Improvement in the drug product	None	01/26/2023	PAR	7	None	None	7.96	None	2013	25.29	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2023	68084092125	CYCLOSPORINE CAPSULE 100MG 30UD	Generic	FDA	11/27/2023	56.56	433.65	None	Non-innovator Multiple Source Drug	306	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2023	60687068001	METHIMAZOLE TAB 10MG 100UD	Generic	FDA	01/31/2023	18.48	82.93	None	Non-innovator Multiple Source Drug	84	None	Market Conditions	None	No Change Improvement in the drug product	None	02/15/2023	Strides Pharma Science	28	None	None	28.14	None	2022	64.45	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2023	60687066901	METHIMAZOLE TAB 5MG 100UD	Generic	FDA	01/31/2023	9.67	59.67	None	Non-innovator Multiple Source Drug	592	None	Market Conditions	None	No Change Improvement in the drug product	None	02/14/2023	Strides Pharma Science	10	None	None	10.82	None	2022	50.00	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2023	68084080521	METHYLPHENIDATE HCL TABLET CII 5MG 30UD	Generic	FDA	10/06/2023	5.00	54.96	None	Non-innovator Multiple Source Drug	5801	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	09/30/2023	68084029121	NALTREXONE HCL TABLET 50MG 30UD	Generic	FDA	07/14/2023	10.52	75.23	None	Non-innovator Multiple Source Drug	5832	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	06/30/2023	68001056600	POTASSIUM CHl ER TAB 10MeQ 100	Generic	FDA	05/01/2023	14.30	47.68	None	Non-innovator Multiple Source Drug	3638	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	06/30/2023	68001056603	POTASSIUM CHl ER TAB 10mEq 500	Generic	FDA	05/01/2023	71.48	238.38	None	Non-innovator Multiple Source Drug	2042	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	06/30/2023	68001056700	POTASSIUM CHl ER TAB 20mEq 100	Generic	FDA	05/01/2023	15.06	50.19	None	Non-innovator Multiple Source Drug	16094	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	06/30/2023	68001056703	POTASSIUM CHl ER TAB 20mEq 500	Generic	FDA	05/01/2023	75.26	250.93	None	Non-innovator Multiple Source Drug	11528	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	06/30/2023	68084049401	PYRIDOSTIGMINE BROMIDE TABLET 60MG 100UD	Generic	FDA	06/05/2023	14.90	138.43	None	Non-innovator Multiple Source Drug	642	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2023	68084005921	ZAFIRLUKAST TABLET 20MG 30UD	Generic	FDA	11/27/2023	13.75	86.10	None	Non-innovator Multiple Source Drug	357	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000128	American Regent	09/30/2023	00517750425	ACETYLCYSTEINE SOLUTION 10%, 4ML, PKG OF 25	Generic	FDA	08/01/2023	6.00	236.50	None	Non-innovator Multiple Source Drug	49139	None	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	No change or Improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000128	American Regent	03/31/2023	00517250210	Caffeine & Sodium Benzoate, 250mg/ml 2mL SDV, 10pk	Generic	Medispan	02/01/2023	18.60	276.10	None	Non-innovator Multiple Source Drug	None	1	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	No change or Improvement	None	None	None	None	None	None	None	None	None	None	None	Caffeine & Sodium Benzoate is not an acquired product.
Rx0000128	American Regent	09/30/2023	00517250210	Caffeine & Sodium Benzoate, 250mg/ml 2mL SDV, 10pk	Generic	Medispan	08/01/2023	20.00	296.10	None	Non-innovator Multiple Source Drug	7115	None	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	No change or Improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000128	American Regent	03/31/2023	00517420125	HYDROXYZINE HCL, 25MG/ML, 1ML SDV, PKG. OF 25	Generic	FDA	02/01/2023	46.50	627.00	None	Non-innovator Multiple Source Drug	None	1	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	Hydroxyzine HCL is not an acquired product.
Rx0000128	American Regent	09/30/2023	00517420125	HYDROXYZINE HCL, 25MG/ML, 1ML SDV, PKG. OF 25	Generic	FDA	08/01/2023	10.75	637.75	None	Non-innovator Multiple Source Drug	6650	None	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	No change or Improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000128	American Regent	03/31/2023	00517560125	HYDROXYZINE HCL, 50MG/ML, 1ML SDV, PKG. OF 25	Generic	FDA	02/01/2023	51.25	691.50	None	Non-innovator Multiple Source Drug	None	1	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	Hydroxyzine HCL is not an acquired product.
Rx0000128	American Regent	09/30/2023	00517560125	HYDROXYZINE HCL, 50MG/ML, 1ML SDV, PKG. OF 25	Generic	FDA	08/01/2023	11.25	703.25	None	Non-innovator Multiple Source Drug	9277	None	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	No change or Improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000128	American Regent	09/30/2023	00517065001	Injectafer Intravenous Solution 750 MG/15ML	Brand	FDA	07/03/2023	26.43	1347.63	None	Single Source Drug	607593	None	American Regent’s US Standards of Business Conduct (available at https://americanregent.com/media/3206/us-sobc-ver-10-01102022.pdf) reflects that it is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	There was no change or improvement.	None	None	None	None	None	None	None	None	None	None	None	We provide the following comment regarding the acquisition fields: Injectafer is not an acquired product. The licensor has granted American Regent the right to develop, manufacture, distribute and sell the product in the United States. American Regent is the NDA holder of this NDC but markets the drug through our parent company, Daiichi Sankyo, Inc.
Rx0000128	American Regent	09/30/2023	00517231005	Venofer (Iron Sucrose) Injection USP, 20 MG/ML 10ML, PKG. OF 5	Brand	FDA	08/01/2023	34.65	612.15	None	Single Source Drug	399870	None	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	No change or Improvement.	None	None	None	None	None	None	None	None	None	None	None	We provide the following comment regarding the patent expiration date field: American Regent does not hold any patents for the drug Venofer that is the subject of the report and therefore has left the patent expiration data element blank. We provide the following comment regarding the acquisition fields: Venofer is not an acquired product.
Rx0000128	American Regent	09/30/2023	00517232510	Venofer (Iron Sucrose) Injection USP, 20 MG/ML 2.5ML, PKG. OF 10	Brand	FDA	08/01/2023	19.80	306.10	None	Single Source Drug	10683	None	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	No change or Improvement.	None	None	None	None	None	None	None	None	None	None	None	We provide the following comment regarding the patent expiration date field: American Regent does not hold any patents for the drug Venofer that is the subject of the report and therefore has left the patent expiration data element blank. We provide the following comment regarding the acquisition fields: Venofer is not an acquired product.
Rx0000128	American Regent	09/30/2023	00517234010	Venofer (Iron Sucrose) Injection USP, 20 MG/ML 5ML, PKG. OF 10	Brand	FDA	08/01/2023	34.70	612.20	None	Single Source Drug	896950	None	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	We provide the following comment regarding the patent expiration date field: American Regent does not hold any patents for the drug Venofer that is the subject of the report and therefore has left the patent expiration data element blank. We provide the following comment regarding the acquisition fields: Venofer is not an acquired product.
Rx0000128	American Regent	09/30/2023	00517234025	Venofer (Iron Sucrose) Injection USP, 20 MG/ML 5ML, PKG. OF 25	Brand	FDA	08/01/2023	86.75	1530.50	None	Single Source Drug	70061	None	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	We provide the following comment regarding the patent expiration date field: American Regent does not hold any patents for the drug Venofer that is the subject of the report and therefore has left the patent expiration data element blank. We provide the following comment regarding the acquisition fields: Venofer is not an acquired product.
Rx0000069	Amgen	03/31/2023	55513084301	Aimovig, 140 mg/mL single-dose prefilled SureClick autoinjector	Brand	FDA	01/04/2023	41.11	737.86	04/01/2039	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Aimovig reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	55513084101	Aimovig, 70 mg/mL single-dose prefilled SureClick autoinjector	Brand	FDA	01/04/2023	41.11	737.86	04/01/2039	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Aimovig reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	55513016001	Blincyto, 35 mcg lyophilized vial, 1 pk	Brand	FDA	01/04/2023	273.00	4900.15	04/06/2030	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Blincyto reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	55513081328	Corlanor, 5mg oral solution AMP, 28 pk	Brand	FDA	01/04/2023	14.76	264.94	None	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available.
Rx0000069	Amgen	03/31/2023	55513080060	Corlanor, 5mg tablet, 60 pk	Brand	FDA	01/04/2023	31.63	567.73	06/12/2027	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Corlanor reflects the date for the latest-expiring patents publicly disclosed in the Orange Book for the approved product, including any pediatric exclusivities.
Rx0000069	Amgen	03/31/2023	55513081060	Corlanor, 7.5mg tablet, 60 pk	Brand	FDA	01/04/2023	31.63	567.73	06/12/2027	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Corlanor reflects the date for the latest-expiring patents publicly disclosed in the Orange Book for the approved product, including any pediatric exclusivities.
Rx0000069	Amgen	03/31/2023	58406004401	Enbrel Mini, 50mg/mL, Cartridge (ML), 1 pack	Brand	FDA	01/04/2023	121.42	1762.33	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	58406004404	Enbrel Mini, 50mg/mL, Cartridge (ML), 4 pack	Brand	FDA	01/04/2023	485.70	7049.34	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	58406003201	Enbrel Sureclick, 50mg/mL, Pen Injector (ML), 1 pack	Brand	FDA	01/04/2023	121.42	1762.33	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	58406003204	Enbrel Sureclick, 50mg/mL, Pen Injector (ML), 4 pack	Brand	FDA	01/04/2023	485.70	7049.34	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	58406042534	Enbrel, 25mg (1 mL), Vial (EA), 4 pack	Brand	FDA	01/04/2023	242.85	3524.69	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	58406042541	Enbrel, 25mg (1mL), Vial (EA), 1 pack	Brand	FDA	01/04/2023	60.71	881.17	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	58406001001	Enbrel, 25mg/0.5mL, Syringe (ML), 1 pack	Brand	FDA	01/04/2023	60.71	881.17	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	58406001004	Enbrel, 25mg/0.5mL, Syringe (ML), 4 pack	Brand	FDA	01/04/2023	242.85	3524.69	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	58406005501	Enbrel, 25mg/0.5mL, Vial (EA), 1 pack	Brand	FDA	01/04/2023	60.71	881.17	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	58406005504	Enbrel, 25mg/0.5mL, Vial (EA), 4 pack	Brand	FDA	01/04/2023	242.85	3524.69	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	58406002101	Enbrel, 50mg/mL, Syringe (ML), 1 pack	Brand	FDA	01/04/2023	121.42	1762.33	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	58406002104	Enbrel, 50mg/mL, Syringe (ML), 4 pack	Brand	FDA	01/04/2023	485.70	7049.34	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	55513088001	Evenity, 105mg, 1.17mL prefilled syringe, 1 pk	Brand	FDA	01/04/2023	62.19	1116.25	04/09/2033	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Evenity reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	06/30/2023	55513088001	Evenity, 105mg, 1.17mL prefilled syringe, 1 pk	Brand	FDA	06/30/2023	42.97	1159.22	04/09/2033	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Evenity reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	55513088002	Evenity, 105mg, 1.17mL prefilled syringe, 2 pk	Brand	FDA	01/04/2023	124.38	2232.49	04/09/2033	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Evenity reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	06/30/2023	55513088002	Evenity, 105mg, 1.17mL prefilled syringe, 2 pk	Brand	FDA	06/30/2023	85.95	2318.44	04/09/2033	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Evenity reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	55513007801	Imlygic, 106 (1 million) PFU/mL (1.0 mL) single-use vial	Brand	FDA	01/04/2023	3.53	63.37	11/23/2025	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Imlygic reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	55513007901	Imlygic, 108 (100 million) PFU/mL (1.0 mL) single-use vial	Brand	FDA	01/04/2023	353.01	6336.31	11/23/2025	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Imlygic reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	76075010301	Kyprolis, 10 mg (2mg/mL) lyophilized vial, 1 pk	Brand	FDA	01/04/2023	27.66	496.53	05/08/2033	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Kyprolis reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	76075010201	Kyprolis, 30 mg (2mg/mL) lyophilized vial, 1 pk	Brand	FDA	01/04/2023	82.99	1489.60	05/08/2033	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Kyprolis reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	76075010101	Kyprolis, 60 mg lyophilized vial, 1 pk	Brand	FDA	01/04/2023	165.98	2979.20	05/08/2033	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Kyprolis reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	55513022301	Nplate, 125 mcg, 0.25mL (500 mcg/mL) single-use vial	Brand	FDA	01/04/2023	66.44	1192.50	02/12/2028	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Nplate reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	55513022101	Nplate, 250 mcg, 0.5mL (500 mcg/mL) single-use vial	Brand	FDA	01/04/2023	132.87	2384.97	02/12/2028	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Nplate reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	55513022201	Nplate, 500 mcg, 1.0mL (500 mcg/mL) single-use vial	Brand	FDA	01/04/2023	265.75	4769.93	02/12/2028	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Nplate reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	55513036955	Otezla, 10mg (4)-20mg (4)-30g (47), Tablet Dose Pack, 55 pack	Brand	FDA	01/04/2023	256.30	4600.48	05/29/2034	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	11/21/2019	Celgene	13400000000	None	None	3398.00	3283.09	2020	3591.69	None	This is a new Amgen NDC that we are reassigning from the old Celgene NDC. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Otezla reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	55513013760	Otezla, 30mg, Tablet, 60 pack	Brand	FDA	01/04/2023	256.30	4600.48	05/29/2034	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	11/21/2019	Celgene	13400000000	None	None	3398.00	3283.09	2020	3591.69	None	This is a new Amgen NDC that we are reassigning from the old Celgene NDC. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Otezla reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	55513071001	Prolia, 60 mg, 1.0mL (60 mg/mL) prefilled syringe	Brand	FDA	01/04/2023	87.15	1564.31	02/19/2025	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Prolia reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	06/30/2023	55513071001	Prolia, 60 mg, 1.0mL (60 mg/mL) prefilled syringe	Brand	FDA	06/30/2023	60.23	1624.54	02/19/2025	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Prolia reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	72511076002	Repatha, 140 mg, 1.0 mL (140 mg/mL) autoinjector, 2 pack	Brand	FDA	01/04/2023	30.67	550.48	10/08/2030	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Repatha reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	72511075001	Repatha, 140 mg, 1.0 mL (140 mg/mL) prefilled syringe	Brand	FDA	01/04/2023	15.33	275.24	10/08/2030	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Repatha reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	72511077001	Repatha, 420 mg, 3.5 mL (120 mg/mL)  Pushtronex system	Brand	FDA	01/04/2023	33.22	596.35	10/08/2030	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Repatha reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	55513095401	Vectibix, 100 mg, 5 mL (20 mg/mL) single-use vial	Brand	FDA	01/04/2023	87.44	1569.46	None	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available.
Rx0000069	Amgen	03/31/2023	55513095601	Vectibix, 400 mg, 20 mL (20 mg/mL) single-use vial	Brand	FDA	01/04/2023	349.76	6277.82	None	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available.
Rx0000069	Amgen	03/31/2023	55513073001	Xgeva, 120 mg /1.7 mL (70 mg/mL) single-use vial	Brand	FDA	01/04/2023	160.31	2877.46	02/19/2025	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Xgeva reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	06/30/2023	55513073001	Xgeva, 120 mg /1.7 mL (70 mg/mL) single-use vial	Brand	FDA	06/30/2023	110.78	2988.24	02/19/2025	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Xgeva reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000122	Amneal Pharmaceuticals	12/31/2023	70121171109	Dexmedetomine HCl 9% NaCl IV 24 Single Dose Bags	Generic	FDA	11/17/2023	237.50	427.50	None	Non-innovator Multiple Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	Amneal considers the process of assessing and developing price actions to be a trade secret using confidential information and cannot release this data into the public domain.
Rx0000122	Amneal Pharmaceuticals	03/31/2023	64896066930	Emverm Oral Tablet Chewable 100 MG	Generic	FDA	02/01/2023	55.64	617.65	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	64896069701	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 10 MG 100	Generic	FDA	02/01/2023	139.15	838.42	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	64896069713	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 10 MG 60	Generic	FDA	02/01/2023	83.49	503.06	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	64896069801	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 15 MG 100	Generic	FDA	02/01/2023	192.97	1162.66	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	64896069813	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 15 MG 60	Generic	FDA	02/01/2023	115.78	697.61	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	64896069901	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 20 MG 100	Generic	FDA	02/01/2023	246.81	1487.03	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	64896069913	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 20 MG 60	Generic	FDA	02/01/2023	148.08	892.22	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	64896070001	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 30 MG 100	Generic	FDA	02/01/2023	355.23	2140.33	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	64896070013	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 30 MG 60	Generic	FDA	02/01/2023	213.14	1284.21	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	64896070101	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 40 MG 100	Generic	FDA	02/01/2023	463.67	2793.66	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	64896070113	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 40 MG 60	Generic	FDA	02/01/2023	278.20	1676.20	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	64896069501	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 5 MG 100	Generic	FDA	02/01/2023	72.47	436.63	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	64896069513	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 5 MG 60	Generic	FDA	02/01/2023	43.48	261.96	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	64896069601	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 7.5 MG 100	Generic	FDA	02/01/2023	105.81	637.49	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	64896069613	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 7.5 MG 60	Generic	FDA	02/01/2023	63.48	382.49	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	64896066101	Rytary Oral Capsule Extended Release 23.75-95 MG	Brand	FDA	02/01/2023	30.78	415.48	12/26/2028	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	64896066201	Rytary Oral Capsule Extended Release 36.25-145 MG	Brand	FDA	02/01/2023	30.78	415.48	12/26/2028	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	64896066301	Rytary Oral Capsule Extended Release 48.75-195 MG	Brand	FDA	02/01/2023	30.78	415.48	12/26/2028	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	64896066401	Rytary Oral Capsule Extended Release 61.25-245 MG	Brand	FDA	02/01/2023	38.67	522.08	12/26/2028	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	60846080501	Unithroid Oral Tablet 100 MCG	Brand	FDA	02/01/2023	29.33	400.48	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	60846080601	Unithroid Oral Tablet 112 MCG	Brand	FDA	02/01/2023	29.38	401.28	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	60846080701	Unithroid Oral Tablet 125 MCG	Brand	FDA	02/01/2023	29.43	401.95	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	60846080801	Unithroid Oral Tablet 137 MCG	Brand	FDA	02/01/2023	29.46	402.37	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	60846080901	Unithroid Oral Tablet 150 MCG	Brand	FDA	02/01/2023	29.48	402.69	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	60846081001	Unithroid Oral Tablet 175 MCG	Brand	FDA	02/01/2023	29.53	403.30	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	60846081101	Unithroid Oral Tablet 200 MCG	Brand	FDA	02/01/2023	29.56	403.68	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	60846080101	Unithroid Oral Tablet 25 MCG	Brand	FDA	02/01/2023	29.15	398.21	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	60846081201	Unithroid Oral Tablet 300 MCG	Brand	FDA	02/01/2023	29.58	404.08	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	60846080201	Unithroid Oral Tablet 50 MCG	Brand	FDA	02/01/2023	29.17	398.47	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	60846080301	Unithroid Oral Tablet 75 MCG	Brand	FDA	02/01/2023	29.21	398.92	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	60846080401	Unithroid Oral Tablet 88 MCG	Brand	FDA	02/01/2023	29.27	399.80	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000176	ANIP	03/31/2023	62559030690	Lipofen Capsules 150mg 90ct	Brand	FDA	03/20/2023	84.50	938.08	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000176	ANIP	03/31/2023	62559030590	Lipofen Capsules 50mg 90ct	Brand	FDA	03/20/2023	38.56	428.09	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000412	Antares Pharma, Inc	03/31/2023	54436020004	Xyosted (Testosterone Enanthate) once weekly subcutaneous autoinjector 100MG/0.5ML; 4 syringes in 1 carton	Brand	FDA	01/03/2023	28.86	606.21	08/30/2038	Single Source Drug	10000	None	Cost of marketing & distribution	None	Improved marketing/distribution channels	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000412	Antares Pharma, Inc	03/31/2023	54436025004	Xyosted (Testosterone Enanthate) once weekly subcutaneous autoinjector 50MG/0.5ML; 4 syringes in 1 carton	Brand	FDA	01/03/2023	28.86	606.21	08/30/2038	Single Source Drug	15000	None	Cost of marketing & distribution	None	Improved marketing/distribution channels	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000412	Antares Pharma, Inc	03/31/2023	54436027504	Xyosted (Testosterone Enanthate) once weekly subcutaneous autoinjector 75MG/0.5ML; 4 syringes in 1 carton	Brand	FDA	01/03/2023	28.86	606.21	08/30/2038	Single Source Drug	40000	None	Cost of marketing & distribution	None	Improved marketing/distribution channels	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000271	Apotex Corp	09/30/2023	60505437703	PAXIL CR FCT 12.5MG 30BTL USA	Brand	FDA	07/01/2023	4.67	276.01	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	A number of considerations impact pricing decisions. These factors include but are not limited to the value the product brings to patients, product market competitiveness, patient out-of-pocket costs, corporate investments in important clinical development initiatives, as well as the cost of labor and goods.
Rx0000271	Apotex Corp	09/30/2023	60505437803	PAXIL CR FCT 25MG 30BTL USA	Brand	FDA	07/01/2023	4.67	288.01	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	A number of considerations impact pricing decisions. These factors include but are not limited to the value the product brings to patients, product market competitiveness, patient out-of-pocket costs, corporate investments in important clinical development initiatives, as well as the cost of labor and goods.
Rx0000271	Apotex Corp	09/30/2023	60505437903	PAXIL CR FCT 37.5MG 30BTL USA	Brand	FDA	07/01/2023	4.67	296.69	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	A number of considerations impact pricing decisions. These factors include but are not limited to the value the product brings to patients, product market competitiveness, patient out-of-pocket costs, corporate investments in important clinical development initiatives, as well as the cost of labor and goods.
Rx0000271	Apotex Corp	09/30/2023	60505451703	PAXIL FCT 10MG 30BTL USA	Brand	FDA	07/01/2023	4.67	267.98	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	A number of considerations impact pricing decisions. These factors include but are not limited to the value the product brings to patients, product market competitiveness, patient out-of-pocket costs, corporate investments in important clinical development initiatives, as well as the cost of labor and goods.
Rx0000271	Apotex Corp	09/30/2023	60505451803	PAXIL FCT 20MG 30BTL USA	Brand	FDA	07/01/2023	4.67	279.59	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	A number of considerations impact pricing decisions. These factors include but are not limited to the value the product brings to patients, product market competitiveness, patient out-of-pocket costs, corporate investments in important clinical development initiatives, as well as the cost of labor and goods.
Rx0000271	Apotex Corp	09/30/2023	60505451903	PAXIL FCT 30MG 30BTL USA	Brand	FDA	07/01/2023	4.67	288.06	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	A number of considerations impact pricing decisions. These factors include but are not limited to the value the product brings to patients, product market competitiveness, patient out-of-pocket costs, corporate investments in important clinical development initiatives, as well as the cost of labor and goods.
Rx0000271	Apotex Corp	09/30/2023	60505452003	PAXIL FCT 40MG 30BTL USA	Brand	FDA	07/01/2023	4.67	304.29	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	A number of considerations impact pricing decisions. These factors include but are not limited to the value the product brings to patients, product market competitiveness, patient out-of-pocket costs, corporate investments in important clinical development initiatives, as well as the cost of labor and goods.
Rx0000141	Ascend Laboratories, LLC	03/31/2023	67877067870	Tobramycin Inhalation Solution 300mg 5ML	Generic	FDA	03/01/2023	301.30	657.42	None	Non-innovator Multiple Source Drug	1300	None	Newly launched product and new contracts with additional rebates and administrative fees. Increased API costs in India.	None	Newly launched product and new contracts with additional rebates and administrative fees. Increased API costs in India.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000277	Avion Pharmaceuticals, LLC	03/31/2023	75854060203	Balcoltra Oral Tablet 0.1-20 MG-MCG(21) pkg size 28 pkg quantity 3	Brand	FDA	01/02/2023	66.15	801.14	None	Non-innovator Multiple Source Drug	95100	None	increase in manufacturing costs	None	none	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000277	Avion Pharmaceuticals, LLC	03/31/2023	75854060228	Balcoltra Oral Tablet inner sleeve 0.1-20 MG-MCG(21) pkg size 28 pkg quantity 1	Brand	FDA	01/02/2023	22.05	267.05	None	Non-innovator Multiple Source Drug	0	1	increase in manufacturing costs	None	none	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000108	AvKare	03/31/2023	42291026130	Entecavir 0.5mg Tablet	Generic	FDA	02/03/2023	292.14	395.00	None	Non-innovator Multiple Source Drug	None	1	AvKARE is a repackager of pharmaceuticals. Our increase factors are due to an increase in cost of goods which include the cost of the pill, bottle, bottle cap, inserts and packaging costs from the packager.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000108	AvKare	03/31/2023	42291026230	Entecavir 1mg Tablet	Generic	FDA	02/03/2023	288.58	395.00	None	Non-innovator Multiple Source Drug	None	1	AvKARE is a repackager of pharmaceuticals. Our increase factors are due to an increase in cost of goods which include the cost of the pill, bottle, bottle cap, inserts and packaging costs from the packager.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000429	Axsome Therapeutics, Inc.	03/31/2023	81968035101	Sunosi Tablets 150mg 1	Brand	FDA	01/01/2023	67.95	822.95	06/17/2024	Single Source Drug	0	1	None	1	None	1	05/09/2022	Jazz Pharmaceuticals, Inc.	53000000	None	Axsome aquired Sunosi with a total upfront payment of $53 million, a high single-digit royalty on Axsome’s U.S. net sales of Sunosi in the current indication, and a mid single-digit royalty on Axsome’s U.S. net sales of Sunosi in future indications.	755.00	699.60	2019	660.00	None	None
Rx0000429	Axsome Therapeutics, Inc.	03/31/2023	68727035101	Sunosi Tablets 150mg 30 Jazz	Brand	Medispan	01/01/2023	67.95	822.95	06/17/2024	Single Source Drug	0	1	None	1	None	1	05/09/2022	Jazz Pharmaceuticals, Inc.	53000000	None	Axsome aquired Sunosi with a total upfront payment of $53 million, a high single-digit royalty on Axsome’s U.S. net sales of Sunosi in the current indication, and a mid single-digit royalty on Axsome’s U.S. net sales of Sunosi in future indications.	755.00	699.60	2019	660.00	None	None
Rx0000429	Axsome Therapeutics, Inc.	03/31/2023	81968035001	Sunosi Tablets 75mg 1	Brand	FDA	01/01/2023	67.95	822.95	06/17/2024	Single Source Drug	0	1	None	1	None	1	05/09/2022	Jazz Pharmaceuticals, Inc.	53000000	None	Axsome aquired Sunosi with a total upfront payment of $53 million, a high single-digit royalty on Axsome’s U.S. net sales of Sunosi in the current indication, and a mid single-digit royalty on Axsome’s U.S. net sales of Sunosi in future indications.	755.00	699.60	2019	660.00	None	None
Rx0000429	Axsome Therapeutics, Inc.	03/31/2023	68727035001	Sunosi Tablets 75mg 30 Jazz	Brand	Medispan	01/01/2023	67.95	822.95	06/17/2024	Single Source Drug	0	1	None	1	None	1	05/09/2022	Jazz Pharmaceuticals, Inc.	53000000	None	Axsome aquired Sunosi with a total upfront payment of $53 million, a high single-digit royalty on Axsome’s U.S. net sales of Sunosi in the current indication, and a mid single-digit royalty on Axsome’s U.S. net sales of Sunosi in future indications.	755.00	699.60	2019	660.00	None	None